Mar 03, 2025 15:41 JST

Source: Eisai

"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
- Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine -

TOKYO, Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of the new nutritional drink “Chocola BB® Nightwell” (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. The productbelongs to the Chocola BB brand, which supports people’s beauty and health, and will be available at pharmacy and drugstores throughout Japan.

Chocola BB Nightwell contains eight active ingredients, including vitamin B2, which supports fatmetabolism and converts it into energy, and glycine, which improves sleep quality associated with poornutrition, as well as herbal medicines (Crataegus oxyacantha and Citrus unshiu peel). With a grapefruit flavor, Chocola BB Nightwell is easy to drink, low in calories (5.1 kcal per bottle), and caffeine-free, allowing consumption before bedtime. By promoting fatigue recovery during sleep, Chocola BB Nightwell supports a refreshed start to the day.

Since the launch of Chocola BB tablets in 1952, the Chocola BB brand has been offering products forover 70 years to address various skin and fatigue symptoms, in line with the needs of each era. The current Chocola BB drink lineup consists of designated quasi-drugs for fatigue care, including “ChocolaBB® Light” for daily fatigue, “Chocola BB® Royal 2” for severe fatigue, and “Chocola BB® Hyper” for low vitality.

By marketing the Chocola BB series of products, Eisai is committed to addressing the diverse needswithin fatigue care, and supporting the beauty and wellness of even more people.

Please refer to the product’s website for details about Chocola BB Nightwell (Japanese only) www.eisai.jp/products/chocola/chocola_bb_nightwell

FOr more information, visit https://www.eisai.com/news/2025/news202514.html

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
 
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
More Press release >>

Latest Press Release


More Latest Release >>